Abstract:Background: Concomitant chemoradiotherapy is the standard treatment of unresectable stage III non-small cell lung cancer (NSCLC). However, the optimal chemotherapy regimen is still controversial. We have conducted a phase II clinical trial in a Chinese population to evaluate concomitant treatment using pemetrexed/carboplatin chemotherapy and thoracic radiotherapy followed by pemetrexed/carboplatin consolidation chemotherapy in these patients. The purpose of this study is to evaluate the feasibility and activity, and also assess its impact on progression-free survival (PFS).Patients and methods: A total of 21 patients were enrolled between January 2008 and October 2009. Patients received concomitant pemetrexed 500 mg/m(2), carboplatin area under the curve (AUC) 5 chemotherapy on day 1 repeated every 3 weeks for 2 cycles and thoracic radiotherapy, followed by pemetrexed/carboplatin for 3 cycles as consolidation therapy. Objective response rate according to the RECIST criteria was recorded and toxicity was evaluated using the NCI Common Toxicity Criteria. The Kaplan-Meier method was used to evaluate patient survival. Univariate analysis of patient characteristics and tumor responses was conducted using the Chi-square and Fisher's exact test.Results: Five (23.8%) and 13 patients (61.9%) had a complete or partial response, respectively, while 2 patient's disease remained stable and 1 patient had progression of the disease. The overall response rate (85.7%, 95% confidence interval (Cl): 61-97%) exceeded the goal per study design. The median PFS was 12.0 months (95% CI: 10.6-13.4 months). The statistical analysis of predictive factors of efficacy revealed that the response rate and PFS seemed to a trend favoring adenocarcinoma histology. Main toxicity (grade 3 or greater, %): neutropenia 6 (28.5%): thrombocytopenia 4 (19%); anaemia 5(23.8%); nausea/vomiting 1 (4.8%); anorexia 1 (4.8%), dysphagia 2 (9.5%), radiation pneumonitis 1(4.8%) and fatigue 2 (9.5%).Conclusion: This data suggests that concomitant treatment with pemetrexed/carboplatin at full systemic doses and thoracic radiotherapy was well tolerated, with promising activity in a Chinese population with unresectable stage III NSCLC. Better outcomes were observed in patients with adenocarcinoma in this study. Although the data presented herewith appears promising, this study is relatively small, and more data from randomized trials are needed to further validate this regimen. (C) 2010 Elsevier Ireland Ltd. All rights reserved.

Clinical study of gemcitabine with a sensitizer of concurrent radiotherapy in locally advanced non-small cell lung cancer

Phase II Trial of a 2-H Infusion of Gemcitabine Plus Carboplatin As First-Line Chemotherapy for Advanced Non-Small-cell Lung Cancer

Phase II Study of Gemcitabine and Carboplatin in Patients with Advanced Non-Small-cell Lung Cancer.

Clinical Benefit of Gemcitabine Plus Cisplatin 3-Week Regimen for Patients with Advanced Non-Small Cell Lung Cancer: a Prospective Observational Study.

Clinical trial of advanced non-small cell lung cancer by combination of gemci-tabine and cisplatin

Three dimensional-conformal radiotherapy combined with gemcitabine chemotherapy for locally advanced non-small cell lung cancer

Phase II Trial of a 2-Hour Infusion of Gemcitabine Plus Carboplatin As First-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer

[A Clinical Study on the Combination of Gemcitabine and Cisplatin in the Treatment of Advanced Non-Small Cell Lung Cancer].

Gemcitabine Plus Cisplatin Combination in the Treatment of 16 Cases with Advanced Non Small Cell Lung Cancer

Gemcitabine Plus Oxaliplatin Combination in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer

Radiotherapy Combined with Gefitinib for Patients with Locally Advanced Non-Small Cell Lung Cancer Who Are Unfit for Surgery or Concurrent Chemoradiotherapy: a Phase II Clinical Trial

Efficacy of Combined Gemcitabine and Cisplatin in the Treatment of Advanced Non-Small Cell Lung Cancer

Clinical Study of Three-Dimensional Conformal Radiotherapy Combined with Concurrent and Sequential Gemcitabine Chemotherapy for Stage Ⅲ Non-Small Cell Lung Cancer in Elderly Patients

Clinical Effects of Gemcitabine Combined with Pemetrexed on Patients with Advanced Non-Small Cell Lung Cancer

Observation on Curative Effects of Concurrent Radiotherapy and Chemotherapy for Advanced Non-small-cell Lung Cancer

Clinical Study on Accurate Radiotherapy Combined with Chemotherapy in the Treatment of Middle and Advanced Non-Small Cell Lung Cancer

Clinical Evaluation of delayed infusion of low dose gemcitabine combined with cisplatin maintenance chemotherapy regimens for treatment of advanced NSCLC patients

The Clinical Study on the efficacy and safety of gemcitabine combined with vinorelbine in the Treatment of Advanced Non-small Cell Lung Cancer

Clinical Study on Concurrent Hypofractionated High-Dose Radiotherapy and Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer

Concomitant Chemoradiotherapy Using Pemetrexed and Carboplatin for Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC): Preliminary Results of a Phase II Study

Efficacy of Gemcitabine Combined with Different Platinum Agents for Early Treatment of Advanced NSCLC